文献速递精神分裂症与精神病性障碍物质与行为成瘾

物质使用障碍与精神分裂症多基因易感性的关联

Association Between Substance Use Disorder and Polygenic Liability to Schizophrenia.
PubMed 文献 · Biol Psychiatry · 2017-06-06

研究检验共享遗传易感性是否解释精神分裂症与物质使用障碍的高共病率,在三个物质使用障碍数据集中计算精神分裂症多基因风险评分。各数据集及合并分析均显示任何物质使用障碍诊断与精神分裂症多基因风险评分强关联,提示共病部分归因于共享多基因易感性。

要点

  • 精神分裂症多基因风险评分与任何物质使用障碍诊断在三个数据集中均强关联。
  • 合并分析中关联的伪R2范围为0.8-3.7%,最小p值为4×10^-23。
  • 共享易感性更符合物质使用障碍的一般风险,而非各物质特异风险。

核心结论

  • 精神分裂症与物质使用障碍的共病部分可归因于共享的多基因易感性。
  • 共享易感性更符合物质使用障碍的一般风险,而非特定物质使用障碍的特异风险。
  • 结果支持精神分裂症与物质使用障碍之间边界模糊的证据。

研究设计与样本

  • 研究假设共享遗传易感性导致精神分裂症与物质使用障碍的高共病率。
  • 使用精神分裂症多基因风险评分,在三个物质使用障碍数据集中进行分析。
  • 数据集包括烟草使用障碍(918例/988对照)、酒精使用障碍(643例/384对照)和可卡因使用障碍(210例/317对照)。
  • 表型在三个数据集间统一,并执行标准化分析;基因型填充至1000 Genomes参考面板。

主要发现

  • 在每个单独数据集和合并分析中,任何物质使用障碍诊断与精神分裂症多基因风险评分均呈强关联。
  • 合并分析的伪R2范围为0.8-3.7%,最小p值为4×10^-23。

临床怎么用

  • 提示临床评估物质使用障碍时应考虑共享遗传易感性,尤其精神分裂症患者。
  • 支持对精神分裂症患者常规筛查物质使用障碍,反之亦然。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are high levels of comorbidity between schizophrenia and substance use disorder, but little is known about the genetic etiology of this comorbidity. METHODS: We tested the hypothesis that shared genetic liability contributes to the high rates of comorbidity between schizophrenia and substance use disorder. To do this, polygenic risk scores for schizophrenia derived from a large meta-analysis by the Psychiatric Genomics Consortium were computed in three substance use disorder datasets: the Collaborative Genetic Study of Nicotine Dependence (ascertained for tobacco use disorder; n = 918 cases; 988 control subjects), the Collaborative Study on the Genetics of Alcoholism (ascertained for alcohol use disorder; n = 643 cases; 384 control subjects), and the Family Study of Cocaine Dependence (ascertained for cocaine use disorder; n = 210 cases; 317 control subjects). Phenotypes were harmonized across the three datasets and standardized analyses were performed. Genome-wide genotypes were imputed to the 1000 Genomes reference panel. RESULTS: In each individual dataset and in the mega-analysis, strong associations were observed between any substance use disorder diagnosis and the polygenic risk score for schizophrenia (mega-analysis pseudo-R2 range 0.8-3.7%; minimum p = 4 × 10-23). CONCLUSIONS: These results suggest that comorbidity between schizophrenia and substance use disorder is partially attributable to shared polygenic liability. This shared liability is most consistent with a general risk for substance use disorder rather than specific risks for individual substance use disorders and adds to increasing evidence of a blurred boundary between schizophrenia and substance use disorder.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Hartz SM, Horton AC, Oehlert M, et al. Association Between Substance Use Disorder and Polygenic Liability to Schizophrenia. Biol Psychiatry. 2017. PMID: 28739213. doi:10.1016/j.biopsych.2017.04.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。